* Imutec Corp., of Toronto, said it completeddevelopment and validation of a new potency assay forVirulizin, and is preparing to file documents torecommence clinical trials of the cancer drug in Canada,and start studies in the U.S. Trials were delayed inOctober 1994, while the company developed a reliableassay.

* Procept Inc., of Cambridge, Mass., will reconfigure thedosing regimen in a Phase I/II trial of PRO 2000 for HIV.Patients in the Amsterdam study were having side effectsassociated with the continuous infusion protocol.

* Texas Biotechnology Corp., of Houston, said patientenrollment has begun in a Phase II trial assessing itsthrombin inhibitor, Novastan, as an adjunct to t-PA inpatients with acute myocardial infarction.

(c) 1997 American Health Consultants. All rights reserved.